New Diabetes Drug Approved for Once a Week Dosage

.

New Diabetes Drug Approved for Once a Week Dosage

It has been recently revealed in a report that the new proposal of Amylin Pharmaceutical company for a more convenient and novel type of diabetes drug has been approved by the Food and Drug Administration. This shall now give way for a new type of Type 2 diabetes drug, which can be conveniently registered to people merely once a week and this would be able to give the people a better control over their disease and they would be able to live life happily and without any fears.

The name of the drug is Byudereon and this will be able to provide help to people suffering from diabetes, only by being administered once a week. There is a competitor drug for the same being developed by Novo Nordisk medical firm, and the name of this drug is Victoza, which shall also be injected once a day.

It has also been rumored that the celebrity chef Paula Deen is going to be the ambassador for their drug, who has apparently recently been diagnosed of diabetes herself.

"Think for a moment how much easier their lives would be by taking a drug just once a week, a drug that offers solid glucose control, does not require glucose monitoring and comes with added benefit of weight loss", revealed David Kliff, publisher of Diabetic Investor.

There is need for the patients of the disease to stay focused on maintaining a healthy life, with good habits of food and exercise. This alone can let them lead a healthy and balanced life, with no types of physical problems ahead of them. People with diabetes need to restrict and control their eating habits, in order to maintain the balance.


Latest News

Staples to see Protests from Postal Workers
Even Though Boeing Profit’s Fall by 12.7%
It’s Time for a makeover for Ronald McDonald
Stockpiles Scale in U.S but Brent Steady
Qualcomm’s Growth in China Slowed as Customers Wait for New Technology
Mark Pincus Withdraws from Operations of Zynga Amid Restructuring Plans
Kiwi Rises as RBNZ Hikes Interest Rates
Housing Supply Less Than Home Buyer Demand
GE Plans to Bid for Alstom
Valeant Gains Following Takeover Bid But Slips Again
Abortion-rights advocates condemn mid-pregnancy abortion ban
Californian mother reaches settlement over breast milk dispute with TSA